RxDoctor Payments Data

Hedayatollah Zaghi, MD

Cardiovascular Disease · Atlantis, FLNPI 1750364071

Payments from drug & device makers

$2,197in general payments, 2019–2025

Across 93 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • Abbott$243
  • Philips North America LLC$189
  • Lilly USA, LLC$156
  • Amgen$112
  • E.r. Squibb & Sons, L.L.C.$81
  • plus $315 from 9 others

What the payments were for

  • Food & beverage$2,18099%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,197 in reported general payments places this provider in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$524,981
Medicare patients
867
Services billed
4,490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban257$316,296
EntrestoSacubitril/Valsartan115$182,620
MounjaroTirzepatide92$105,112
Repatha SureclickEvolocumab51$52,691
JardianceEmpagliflozin30$43,917
Repatha PushtronexEvolocumab25$26,358
XareltoRivaroxaban19$25,972
RybelsusSemaglutide11$17,583
OzempicSemaglutide19$16,907
Rosuvastatin Calcium792$11,505
Eplerenone83$5,235
Ezetimibe181$4,714
Metoprolol Succinate240$4,002
Prasugrel Hcl44$2,953
Colchicine24$2,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,100$182,620115 claims
Lilly USA, LLCMounjaro$156$105,11292 claims
Novo NordiskRybelsus, Ozempic$54$34,49030 claims
Johnson & JohnsonXarelto$57$25,97219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Atlantis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →